BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

540 related articles for article (PubMed ID: 27016501)

  • 1. The role of interleukin-6 signaling in nervous tissue.
    Rothaug M; Becker-Pauly C; Rose-John S
    Biochim Biophys Acta; 2016 Jun; 1863(6 Pt A):1218-27. PubMed ID: 27016501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of blockade of peripheral interleukin-6 trans-signaling on hippocampus-dependent and independent memory in mice.
    Braun O; Dewitz C; Möller-Hackbarth K; Scheller J; Schiffelholz T; Baier PC; Rose-John S
    J Interferon Cytokine Res; 2013 May; 33(5):254-60. PubMed ID: 23215755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-6 and its receptors: a highly regulated and dynamic system.
    Wolf J; Rose-John S; Garbers C
    Cytokine; 2014 Nov; 70(1):11-20. PubMed ID: 24986424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The balance of interleukin (IL)-6, IL-6·soluble IL-6 receptor (sIL-6R), and IL-6·sIL-6R·sgp130 complexes allows simultaneous classic and trans-signaling.
    Baran P; Hansen S; Waetzig GH; Akbarzadeh M; Lamertz L; Huber HJ; Ahmadian MR; Moll JM; Scheller J
    J Biol Chem; 2018 May; 293(18):6762-6775. PubMed ID: 29559558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different Soluble Forms of the Interleukin-6 Family Signal Transducer gp130 Fine-tune the Blockade of Interleukin-6 Trans-signaling.
    Wolf J; Waetzig GH; Chalaris A; Reinheimer TM; Wege H; Rose-John S; Garbers C
    J Biol Chem; 2016 Jul; 291(31):16186-96. PubMed ID: 27226573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor.
    Garbers C; Thaiss W; Jones GW; Waetzig GH; Lorenzen I; Guilhot F; Lissilaa R; Ferlin WG; Grötzinger J; Jones SA; Rose-John S; Scheller J
    J Biol Chem; 2011 Dec; 286(50):42959-70. PubMed ID: 21990364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of interleukin-6 classic- and trans-signaling on liver damage and regeneration.
    Drucker C; Gewiese J; Malchow S; Scheller J; Rose-John S
    J Autoimmun; 2010 Feb; 34(1):29-37. PubMed ID: 19717281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer.
    Rose-John S; Scheller J; Elson G; Jones SA
    J Leukoc Biol; 2006 Aug; 80(2):227-36. PubMed ID: 16707558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6.
    Rose-John S
    Int J Biol Sci; 2012; 8(9):1237-47. PubMed ID: 23136552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble gp130 prevents interleukin-6 and interleukin-11 cluster signaling but not intracellular autocrine responses.
    Lamertz L; Rummel F; Polz R; Baran P; Hansen S; Waetzig GH; Moll JM; Floss DM; Scheller J
    Sci Signal; 2018 Oct; 11(550):. PubMed ID: 30279168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A soluble form of the interleukin-6 family signal transducer gp130 is dimerized via a C-terminal disulfide bridge resulting from alternative mRNA splicing.
    Wolf J; Waetzig GH; Reinheimer TM; Scheller J; Rose-John S; Garbers C
    Biochem Biophys Res Commun; 2016 Feb; 470(4):870-6. PubMed ID: 26809098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-guided optimization of the interleukin-6 trans-signaling antagonist sgp130.
    Tenhumberg S; Waetzig GH; Chalaris A; Rabe B; Seegert D; Scheller J; Rose-John S; Grötzinger J
    J Biol Chem; 2008 Oct; 283(40):27200-7. PubMed ID: 18650419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-6 and its receptor: from bench to bedside.
    Scheller J; Rose-John S
    Med Microbiol Immunol; 2006 Dec; 195(4):173-83. PubMed ID: 16741736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-6 trans-signaling and colonic cancer associated with inflammatory bowel disease.
    Chalaris A; Schmidt-Arras D; Yamamoto K; Rose-John S
    Dig Dis; 2012; 30(5):492-9. PubMed ID: 23108305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Soluble Interleukin 6 Receptor: Advanced Therapeutic Options in Inflammation.
    Rose-John S
    Clin Pharmacol Ther; 2017 Oct; 102(4):591-598. PubMed ID: 28675418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternative intronic polyadenylation generates the interleukin-6 trans-signaling inhibitor sgp130-E10.
    Sommer J; Garbers C; Wolf J; Trad A; Moll JM; Sack M; Fischer R; Grötzinger J; Waetzig GH; Floss DM; Scheller J
    J Biol Chem; 2014 Aug; 289(32):22140-50. PubMed ID: 24973212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-6 trans-signalling in chronic inflammation and cancer.
    Scheller J; Ohnesorge N; Rose-John S
    Scand J Immunol; 2006 May; 63(5):321-9. PubMed ID: 16640655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of interleukin-6-transsignaling via gp130-Fc in hemorrhagic shock and sepsis.
    Mees ST; Toellner S; Marx K; Faendrich F; Kallen KJ; Schroeder J; Haier J; Kahlke V
    J Surg Res; 2009 Dec; 157(2):235-42. PubMed ID: 19589542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dissecting Interleukin-6 Classic- and Trans-Signaling in Inflammation and Cancer.
    Garbers C; Rose-John S
    Methods Mol Biol; 2018; 1725():127-140. PubMed ID: 29322414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The N-terminus of gp130 is critical for the formation of the high-affinity interleukin-6 receptor complex.
    Moritz RL; Ward LD; Tu GF; Fabri LJ; Ji H; Yasukawa K; Simpson RJ
    Growth Factors; 1999; 16(4):265-78. PubMed ID: 10427501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.